# A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

> **NCT01391130** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 110 (actual)

## Conditions studied

- Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** LY2510924
- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT01391130
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-08
- **Primary completion:** 2014-09
- **Final completion:** 2017-02
- **Target enrollment:** 110 (ACTUAL)
- **Why stopped:** Study Terminated due to Insufficient Efficacy
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391130, "A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01391130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*